<DOC>
	<DOCNO>NCT00915551</DOCNO>
	<brief_summary>This Phase III study design assess efficacy safety PEP005 Gel , 0.015 % applied area skin contain 4-8 AK lesion face scalp .</brief_summary>
	<brief_title>A Multi-Center Study Evaluate Efficacy Safety PEP005 ( Ingenol Mebutate ) Gel , When Used Treat Actinic Keratoses Head ( Face Scalp )</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Patient male female least 18 year age Female patient must either : Nonchildbearing potential , postmenopausal Childbearing potential , provide negative serum urine pregnancy test result prior study treatment , rule pregnancy Cosmetic therapeutic procedure within 2 week 2cm select treatment area Treatment immunomodulators , interferon/ interferon inducer systemic medication suppress immune system within 4 week Treatment 5FU , imiquimod , diclofenac , photodynamic therapy : within 8 week 2 cm select treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>